Fig. 6: Synergy of iExoKras^G12D with anti-CTLA-4 for tumor suppression in preclinical studies.

A Schematic of the experimental timeline using KTC GEM. iExoKras^G12D treatment was initiated at day 33 of age until day 44. B, C Representative images (B) and respective quantification (C) of CD4⁺ T cells (CD4), and CD8⁺ T cells (CD8) by immunolabeling in control and iExoKras^G12D treated KTC mice, n = 3 mice per group. D, E Representative images (D) and respective quantification (E) of CK19⁺ and Fas⁺ cells by immunolabeling in control and iExoKras^G12D treated mice, n = 3-4 mice per group. The data presented in panels A-E are analyses of tissues from our earlier study¹⁸. F Schematic of experimental timeline using orthotopic KPC mice. Treatment was initiated at day 12 post tumor implantation and mice euthanized 2 weeks post-treatment (day 26). G Tumor burden ((Pancreas or tumor weights/body weight) *100) of orthotopic KPC mice treated with iExoKras^G12D, control exosomes (CE), Isotypes control (Iso), αCTLA-4 and αPD-1, n = 5 mice per group. H, I Representative images (H), and quantification (I) of CK19 and pERK immunostainings in the indicated groups, n = 3-5 mice per group. J Representative image and respective quantification of CD8, CD19, CD31, and nuclear staining (DAPI) in tertiary lymphoid structure (TLS) in the tumors of mice in the indicated groups, n = 3-5 mice per group. Scale bar: 100 μm. Data are presented as mean +/– SD. Significance was determined by unpaired two-tailed t-test (C, E) or one-way ANOVA with Dunnett’s or Sidaak’s multiple comparisons test (G, I). nd: not detected; HPF, high-power filed; αCTLA-4, anti-CTLA-4; αPD-1, anti-PD-1. Source data is provided as Source Data file.